1. Background {#sec1}
=============

Parkinson\'s disease (PD) is one of the most common age-related progressive neurodegenerative disorders, with no identifiable cause. PD is slightly more common in men than in women in most studies, usually ranging from a 1.2 : 1 ratio up to a 1.5 : 1 ratio \[[@B1]\], and men seem to be at higher risk for PD \[[@B2]--[@B4]\]. The reasons for the increased risk in men are not known; probably "male lifestyle" could account for some of the excess incidence in men \[[@B5]\]. Alternatively, there is increasing evidence from in vitro as well as clinical studies in humans that estrogen may be neuroprotective \[[@B6]\]. Sex-related differences have been reported in the onset of symptoms and type of motor symptoms as well as in medication use \[[@B7], [@B8]\]. Notably, normal human basal ganglia, specifically within the dopamine system, are sexually dimorphic and that may influence the onset and progression of PD \[[@B8]\].

Levodopa is the most efficacious treatment in the management of PD. Unfortunately, chronic use of traditional levodopa/dopa decarboxylase inhibitor formulations is associated with the development of motor complications, such as wearing-off (WO) and dyskinesia that occur in the majority of PD patients. The WO effect, or end-of-dose failure, refers to a decrease in the length of time that each dose of levodopa controls symptoms. "Off" states that result in motor and nonmotor symptoms, freezing of gait (FOG), and falling are disabling for many patients. Considered to be the major source of disability in PD patients, recognition of these complications is critical in order to develop different strategies designed not only to treat these problems when they develop, but also to prevent troublesome complications associated with potential risk factors.

We previously conducted an observational, cross-sectional, multicenter study called*Early DEtection of wEaring off in Parkinson disease* (DEEP Study) \[[@B9], [@B10]\]. The primary goal was to look at the frequency of WO phenomena among a wide population of Italian patients with PD and secondly to assess associated phenomena, such as FOG and nonmotor symptoms, as well as assessing the impact on patient\'s QoL. In our sample WO occurred since the early years of the disease; furthermore younger age, unified Parkinson\'s disease rating scale (UPDRS) part II score, duration of anti-Parkinson (APD) treatment, and female gender were found significantly associated with WO. Our data showed women having an 80.1% higher risk of experiencing WO than men \[[@B9]\]. This exploratory study aimed to further examine what role the "gender factor" in WO would play, that is, to characterize disparities between women and men in frequency and features of WO symptoms. For this purpose, we conducted a post hoc analysis of the DEEP study database. This study is also part of the gender-medicine project (METAGEM), being carried out with the aim to describe clinical outcomes and therapeutic approach by gender, through the analysis of observational studies conducted in Italy, among different therapeutic areas \[[@B11]\].

2. Methods {#sec2}
==========

Patients prospectively recruited were men and women aged 18 years or older, with PD (Hoehn and Yahr Stages 1--5), nondemented, under levodopa (LD), and/or dopamine agonists (DAs) therapy for ≥1 year before the study screening. The full DEEP study design, including complete inclusion/exclusion criteria, has been published \[[@B9]\]. The study was conducted in accordance with Good Clinical Practice and the Declaration of Helsinki. The study protocol and amendments were approved by each local Ethics Committees or Institutional Review Boards of all 37 participating centers (both academic and hospital based) across Italy (Additional file 1). All patients provided written, informed consent before study participation.

During a single visit, neurologists experienced in movement disorders and previously subjected to targeted training acquired standard demographic and detailed clinical information on all participants who met the criteria, via a structured interview and by examination. Therapy was expressed in terms of Levodopa equivalent daily dose (LEDD) \[[@B12]\]. Subjects were assessed with the UPDRS and the Hoehn and Yahr scale (H&Y). The diagnosis of WO was made on both the neurologist evaluation and the basis of the patient self-assessment using the Italian version of the*19-item Wearing-Off Questionnaire* (WOQ-19) \[[@B10]\]. The WOQ-19 consists of 9 items assessing fluctuations of motor symptoms, including tremor, difficulty in speech, weakness, problems with balance, slowness, reduced dexterity, general stiffness, muscle cramps, and difficulty getting out of the chair and 10 items assessing fluctuations of nonmotor symptoms, including anxiety, sweating, mood changes, numbness, panic attacks, cloudy mind/dullness of thinking, abdominal discomfort, experience hot and cold, pain, and aching \[[@B10]\]. For each item, patients were asked to tick whether symptoms were present and whether they improved after the following dose of anti-Parkinson treatment: a cutoff of ≥2 improved symptoms has been previously established to make diagnosis of WO \[[@B10]\].

3. Statistical Analysis {#sec3}
=======================

Descriptive analyses were mean and standard deviation (SD) or median and interquartile range (IQR). Only the fully completed scales were considered evaluable for the statistical analysis. Gender differences analyses were performed on all patients who responded to inclusion-exclusion criteria. Differences in demographics/baseline characteristics between patients with WO and patients with no WO (as assessed using WOQ-19 and the neurologist assessment) were estimated using *t*-test for continuous data and the Chi-square test for categorical data. As post hoc analyses, all*P* values presented are exploratory. Patients with missing data in selected parameters were not evaluated for those parameters. All analyses were performed with SAS v. 9.2 and Enterprise Guide 4.3.

4. Results {#sec4}
==========

Of the 634 patients screened, 617 (97.3%) met the inclusion criteria: 236 (38.2%) were women and 381 (61.8%) were men ([Table 1](#tab1){ref-type="table"}). The excluded patients did not differ significantly on demographic or clinical parameters with respect to the study population \[[@B9]\]. Baseline demographic data are provided in Tables [1](#tab1){ref-type="table"} and [2](#tab2){ref-type="table"}. Evaluation of gender differences in the study sample indicated no difference in age, history of concomitant diseases, caregiver support, body mass index, or coffee consumption. As shown in [Table 1](#tab1){ref-type="table"}, women were less likely to be married/cohabiting (*P* = 0.0001) and have less education (*P* = 0.0002). In almost the third of cases women were housewives and were less likely to be employed (*P* = 0.0046). Men were more likely to be past (*P* \< 0.0001) or current smokers (*P* = 0.0059) and to be frequent alcohol consumers (*P* \< 0.0001), although more often engaged in physical activity on a regular basis (*P* = 0.0005).

A shown in [Table 2](#tab2){ref-type="table"}, disease duration, H&Y staging, and UPDRS and MMSE scores were statistically indistinguishable between both groups. Postural instability/gait difficulties (PIGD) phenotype was found in 53.0% of the whole sample, although more prevalent in women (57.0% versus 50.5%, *P* = 0.005), while the tremor dominant (TD) phenotype was more frequently attributed to men (29.0% versus 41.4%, *P* = 0.005).

Prevalence of WO was higher among women, according to both neurologists\' judgment (61.9% versus 53.8%, *P* = 0.0495) and WOQ-19 analysis (72.5% versus 64.0%, *P* = 0.034) ([Figure 1](#fig1){ref-type="fig"}). Taking into account the symptoms reported as usually improving after the following dose of anti-Parkinson agents (APD), otherwise defined as WO symptoms, 3.3 ± 2.5 versus 3.0 ± 2.6 were motor symptoms (*P* = 0.222) and 1.2 ± 1.8 versus 0.9 ± 1.5 were nonmotor symptoms (*P* = 0.0125), respectively, in women and men. The frequency of symptoms reported by patients through the WOQ-19, stratified by gender and disease duration, is listed in [Table 3](#tab3){ref-type="table"}. Among patients with a diagnosis of WO according to WOQ-19, women experienced ≥1 motor symptom in 72.5% versus 64.0% in men and ≥1 nonmotor symptom in 44.5% versus 36.7%, respectively, in men ([Figure 2](#fig2){ref-type="fig"}).

With regard to APD therapy, no differences were observed in the use of the different classes of APDs (*P* = 0.4457) or for LEDD values (844.2 ± 679.0 versus 874.4 ± 749.1, *P* = 0.622).

Finally, women reported significantly higher PDQ-8 scores than men (31.3 ± 18.4 versus 27.7 ± 19.1, *P* = 0.023).

5. Discussion {#sec5}
=============

WO is an important feature of PD, often marking the end of the "honeymoon period." The WO manifestations can be extremely heterogeneous from subject to subject, and early recognition allows timely optimization of treatment that may impact patient care and long-term clinical outcomes. The reasons underlying these complications are not fully understood and well-recognized risk factors for the development of WO and dyskinesias include young age at onset, low body weight, severity of disease higher levodopa dose, association of levodopa with entacapone, once daily intake of levodopa, duration of levodopa therapy, more severe UPDRS Part II, and female gender \[[@B9], [@B13]--[@B15]\]. This paper was dedicated to assess gender differences in WO and is based on the post hoc analysis of the DEEP study, a large epidemiological survey that enrolled more than 600 patients with PD across Italy. This study specifically investigated for WO and shows that women are more likely to suffer from WO symptoms as compared to men and that female gender confers an increased risk for WO equal to 80.1% \[[@B9]\]. This finding was confirmed both by the neurologist assessment (61.9% versus 53.8%, *P* = 0.049) and by patients themselves thorough the WOQ-19 (72.5% versus 64.0%, *P* = 0.034). Among patients with WO (WOQ-19), women more frequently complained of ≥1 motor (72.5% versus 64.0%) and ≥1 nonmotor (44.5% versus 36.7%) symptoms of WO. Our findings have been supported in a previous clinic-based sample of patients with PD, where WO symptoms have been shown to occur more frequently in women (46% versus 29%, *P* = 0.02) \[[@B16]\]. Furthermore, durations to develop WO and dyskinesia were shown to be shorter in women compared to men, as well as disease progression being slightly faster for women \[[@B17]\]. A similar "gender effect" has already been shown for the occurrence of levodopa-induced dyskinesias, as it has been claimed that dyskinesias occur more frequently in women if disease duration is \>5 years \[[@B18], [@B19]\] and with a shorter time latency than men \[[@B20]\]. Otherwise, in a large British community-based study, men and women did not differ in the occurrence of motor fluctuations or dyskinesias \[[@B13]\]. In a recent post hoc analysis of a large prospective trial, female gender was identified as a specific predicting factor for dyskinesias and WO as well, and the authors hypothesized that it would reflect increased levodopa concentrations in women because of lower body weight \[[@B15]\]. This interesting hypothesis, in addition to providing an explanation of the association with female gender, would place the emphasis on a parameter, such as body weight, which in clinical practice is generally overlooked for therapy decisions. Data available from our observational study do not allow analyzing this aspect, as patients were undergoing very heterogeneous treatments and were poorly comparable to one another.

In DEEP population women and men were substantially homogeneous for age, disease duration, H&Y staging, and neurological disability (UPDRS; MMSE); otherwise smoking habits, alcohol consumption, and physical activity differed, and this reflects what is observed in the general population \[[@B21]\]. To our knowledge no data indicate a direct association of these social factors with WO; nevertheless, it is plausible that they might influence PD treatment and vice versa, and we cannot exclude possible association with the development of WO and contribution for the differences between women and men. Large cohort studies would address these hypotheses.

DEEP women reported poorer QoL than men (*P* = 0.023), probably due to WO, as we have previously reported that the number of motor symptoms (0.34008; *P* \< 0.0001) and nonmotor symptoms of WO (0.33595; *P* \< 0.0001) correlates with PDQ-8 score and that by linear regression analysis the presence of each additional WO symptom, as identified by WOQ-19, corresponds to an increase of 1.15 points of the PDQ-8 score (*P* \< 0.0001) \[[@B9]\].

According to treatment guidelines in PD, the symptomatic control of WO should be obtained by increasing and fractionating the dose of levodopa or by the addition of other drugs, such as DAs, catechol-O-methyl transferase (COMT) inhibitors, or monoamine oxidase inhibitors \[[@B22]--[@B24]\]. Surprisingly, in front of the higher prevalence of WO, DEEP women were indistinctly treated as men, both in terms of classes of APD and by LEDD analysis. This could have several explanations. First, women and men may exhibit different pharmacological response to APD, making a direct comparison between women and men difficult. Although gender differences are generally not acknowledged in published clinical guidelines of PD management, evidence of gender disparities in medication response, pharmacokinetics, and tolerability suggests the need for paying more attention to differences between women and men in clinical management. Levodopa treatment has been found to significantly improve motor function in women more than in men \[[@B25]\]. Studies suggest that women have greater levodopa bioavailability \[[@B26], [@B27]\] and different clearance of dopaminergic agents, which may play a role in gender-specific dosing of PD medications and may explain why women are more likely to have levodopa-related dyskinesias \[[@B18], [@B19], [@B28]\]. The COMT inhibitors have also been reported to have different tolerability profiles based on gender, which may result from disparities in optimal levodopa dosage \[[@B29], [@B30]\].

Second, the higher frequency of WO among women may reflect a state of undertreatment. If this is the case, we may interpret it as a more "gentle" treatment approach adopted for women with PD, compared to men, perhaps due to safety and tolerability concerns. This hypothesis is in line with the findings of a large population-based study including more than 25,000 patients with PD (Thomson Reuter\'s Marketscan), as men were found to be more likely to be treated with an APD in the first year after diagnosis (72.9% versus 67.5%, *P* \< 0.0001) and to be treated adjunctively with APD (23.9% versus 21.3%, *P* \< 0.0001), compared to women \[[@B31]\]. Third, since nonmotor symptoms appeared to more heavily affect WO phenomena in women, clinicians could be oriented to prescribe other nondopaminergic therapies, rather than APD. Among DEEP women, the analysis of individual WO symptoms shows the greater prevalence of nonmotor symptoms such as "anxiety" (23.7% versus 15.2%), "mood changes" (22.0% versus 15.5%), and "pain" (15.7% versus 7.3%). This supports previous observations, where women were found more likely than man to be prescribed an antidepressant (53.1% versus 38.5%, *P* \< 0.0001), an antipsychotic (19.2% versus 14.4%, *P* \< 0.0001), and an anxiolytic (19.6% versus 14.7%, *P* \< 0.0001) \[[@B31]\].

Given the complexity of PD, as well as the potential for patient characteristics to affect WO symptoms and their management, our study allows an initial assessment of the "gender effect" in the WO manifestations and management in the real-world setting. Nevertheless, our study has a number of limitations: (a) as a post hoc analysis it was not originally designed to assess gender differences of WO symptoms; (b) statistical analysis was mainly descriptive and *P* values are only explorative; (c) there are some limitations of the original study, such as patients selection bias and no analysis of non-APD medications; furthermore only symptoms included in WOQ-19 were assessed, which precludes making assumptions about the contribution of other symptoms.

In conclusion, sex differences in WO among subjects with PD appear to exist and may have implications for the optimal utilization of APD therapy. Our results further put in perspective current clinical management of WO symptoms, raising concern about the appropriateness of treatment approach and also the risk of generalizing data derived from trials in which women are often underrepresented. Further research into the long-term implications of these disparities is needed, and studies such as ours, although limited, suggest that "gender effect" should be carefully considered in designing clinical studies in PD.
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###### 

Demographic and lifestyle data of DEEP study population: women versus men.

  -------------------------------------------------------------------------
                                       Women\       Men\         *P*
                                       *N* = 236    *N* = 381    
  ------------------------------------ ------------ ------------ ----------
  Age, mean ± SD                       67.0 ± 8.9   66.6 ± 9.4   0.6602

  Marital status, *N* (%)^\#^                                     

   Married/cohabiting                  168 (71.2)   321 (84.3)   0.0001

   Single                              16 (6.8)     27 (7.1)      

   Divorced/separated                  5 (2.1)      13 (3.4)      

   Widowed                             46 (19.5)    15 (3.9)      

  Employment status, *N* (%)                                      

   Employed                            23 (9.7)     69 (18.1)    0.0046

   Unemployed                          1 (0.4)      6 (1.6)       

   Retired                             130 (55.1)   288 (75.6)    

   Housewife                           75 (31.8)    ---           

   Other                               7 (3.0)      18 (4.7)      

  Education, *N* (%)                                             0.0002

   ≤5 years                            109 (46.2)   113 (29.7)    

   6--8 years                          54 (22.9)    122 (32.0)   0.0002

   \>8 years                           73 (30.9)    146 (38.3)   0.0008

  Caregiver assistance, *N* (%)        49 (20.8)    63 (16.5)    0.2050

  Smoking habit, *N* (%)^\#^                                     \<0.0001

   Smokers                             15 (6.4)     37 (9.7)     0.0059

   Ex-smokers                          32 (13.6)    149 (39.1)   \<0.0001

   Nonsmokers                          183 (77.5)   189 (49.6)    

  Coffee consumers, *N* (%)            162 (68.6)   264 (69.3)   0.6622

  Alcohol consumers, *N* (%)           84 (35.6)    240 (63.0)   \<0.0001

  Regular physical activity, *N* (%)   55 (23.3)    140 (36.7)   0.0005

  BMI, mean ± SD                       24.9 ± 4.5   26.4 ± 3.5    

  Concomitant diseases, *N* (%)        145 (61.4)   205 (53.8)   0.0764

   Hypertension                        75 (31.8)    109 (28.6)    

   Ischemic heart\                     91 (38.6)    137 (36.0)    
    Disease                                                      

   Diabetes mellitus                   20 (8.5)     34 (8.9)      

   Neoplasms                           7 (3.0)      13 (3.4)      

   Cerebrovascular\                    5 (2.1)      4 (1.0)       
    disease                                                      

   Obesity                             3 (1.3)      7 (1.8)       

   Psychiatric\                        9 (3.8)      9 (2.4)       
    disorders                                                    

   Other                               57 (24.2)    72 (18.9)     
  -------------------------------------------------------------------------

^\#^Missing data for \<10 patients/variable.

###### 

Gender differences on clinical aspects of DEEP population: women versus men.

  -----------------------------------------------------------------------------------
                                             Women\          Men\            *P*
                                             *N* = 236       *N* = 381       
  ------------------------------------------ --------------- --------------- --------
  Disease duration, mean ± SD                                                0.389

   \<5 years, *N* (%)                        66 (28.0)       119 (31.2)       

   \>5 years, *N* (%)                        170 (72.0)      262 (68.8)       

  H&Y, *N* (%)^\#^                                                           0.291

   ≤2                                        134 (56.8)      233 (61.1)       

   ≥2.5                                      101 (42.8)      148 (38.6)       

  UPDRS total score, mean ± SD               36.2 ± 17.7     38.1 ± 17.4     0.223

   Part I                                    2.3 ± 2.0       2.1 ± 1.9       0.287

   Part II                                   11.1 ± 6.4      11.3 ± 6.0      0.621

   Part III                                  23.0 ± 11.6     24.6 ± 11.8     0.129

  PD subtypes, *N* (%)^§^                                                    0.006

   TD                                        62 (26.3)       142 (37.3)       

   PIGD                                      120 (50.8)      172 (45.1)      0.0149

   IND                                       29 (12.3)       28 (7.3)        0.0041

  MMSE, mean ± SD                            28.1 ± 1.67     28.2 ± 1.62     0.306

  Anti-Parkinson drugs classes, *N* (%)                                      0.4457

   LD monotherapy                            29 (12.3)       35 (9.2)         

   DA monotherapy                            11 (4.7)        15 (3.9)         

   LD + DA                                   152 (64.4)      234 (61.4)       

   MAOIs                                     84 (35.6)       157 (41.2)       

   COMT inhibitors                           79 (33.5)       132 (34.6)       

  LEDD, mg mean ± SD                         844.2 ± 679.0   874.4 ± 749.1   0.622

  Diagnosis of WO by neurologists, *N* (%)   146 (61.9)      205 (53.8)      0.0495

   \<5 years disease\                        21 (31.8)       38 (31.9)       0.987
    duration                                                                 

   \>5 years disease\                        125 (73.5)      167 (63.7)      0.034
    duration                                                                 

  Diagnosis of WO by WOQ-19, *N* (%)         171 (72.5)      244 (64.0)      0.034

   \<5 years disease\                        37 (56.1)       57 (47.9)       0.2875
    duration                                                                 

   \>5 years disease\                        134 (78.8)      187 (71.4)      0.0834
    duration                                                                 

  PDQ-8, mean ± SD                           31.3 ± 18.4     27.7 ± 19.1     0.023
  -----------------------------------------------------------------------------------

SD: standard deviation; H&Y: Hoehn and Yahr staging; UPDRS: unified Parkinson\'s disease rating scale; PD: Parkinson\'s disease; TD: tremor dominant; PIGD: postural instability and gait difficulties; IND: intermediate; MMSE: mini-mental state examination; LD: levodopa; DA: dopamine-agonist; MAOIs: monoamine oxidase B inhibitors; COMT: catechol-O-methyltransferase; LEDD: levodopa equivalent daily dose; WO: wearing-off; WOQ-19: 19-item wearing-off questionnaire; PDQ-8: 8-item Parkinson\'s disease questionnaire.

^§^PD subtypes could not be calculated for 39 males and 25 females. Paired post hoc Chi-squares take TD as reference.

^\#^Missing data for \<10 patients/variable.

###### 

Frequency of experienced symptoms and WO symptoms, as reported by DEEP population, through the WOQ-19, stratified by disease duration: women versus men.

  Disease duration                                  \<5 years   \>5 years   Total                                  
  ------------------------------------------------- ----------- ----------- ------------ ------------ ------------ ------------
  Referred motor symptoms by WOQ-19, mean ± SD                                                                      
   Experienced                                      4.6 ± 2.2   4.8 ± 2.1   6.0 ± 1.9    5.9 ± 2.0    5.6 ± 2.1    5.5 ± 2.1
   WO                                               2.0 ± 2.1   2.0 ± 2.4   3.8 ± 2.4    3.5 ± 2.6    3.3 ± 2.5    3.0 ± 2.6
  Referred nonmotor symptoms by WOQ-19, mean ± SD                                                                   
   Experienced                                      2.9 ± 2.0   2.3 ± 2.2   4.0 ± 2.3    3.0 ± 2.2    3.7 ± 2.3    2.8 ± 2.2
   WO                                               0.7 ± 1.3   0.5 ± 1.1   1.4 ± 1.9    1.1 ± 1.6    1.2 ± 1.8    0.9 ± 1.5
  Experienced and WO symptoms, mean ± SD                                                                            
   Experienced                                      7.5 ± 3.6   7.1 ± 3.8   9.9 ± 3.6    8.9 ± 3.7    9.3 ± 3.8    8.3 ± 3.8
   WO                                               2.7 ± 2.8   2.4 ± 3.1   5.2 ± 3.9    4.5 ± 3.8    4.5 ± 3.8    3.9 ± 3.7
  Experienced and WO symptoms, *n* (%)                                                                              
   Tremor                                                                                                           
    Experienced                                     48 (72.7)   81 (68.1)   117 (68.8)   180 (68.7)   165 (69.9)   261 (68.5)
    WO                                              29 (43.9)   40 (33.6)   96 (56.5)    127 (48.5)   125 (53.0)   167 (43.8)
   Difficulty in speech                                                                                             
    Experienced                                     14 (21.2)   51 (42.9)   62 (36.5)    152 (58.0)   76 (32.2)    203 (53.3)
    WO                                              8 (12.1)    21 (17.6)   28 (16.5)    76 (29.0)    36 (15.3)    97 (25.5)
   Weakness                                                                                                         
    Experienced                                     48 (72.7)   72 (60.5)   129 (75.9)   184 (70.2)   177 (75.0)   256 (67.2)
    WO                                              14 (21.2)   27 (22.7)   68 (40.0)    102 (38.9)   82 (34.7)    129 (33.9)
   Problems with balance                                                                                            
    Experienced                                     24 (36.4)   49 (41.2)   110 (64.7)   136 (51.9)   134 (56.8)   185 (48.6)
    WO                                              7 (10.6)    18 (15.1)   48 (28.2)    64 (24.4)    55 (23.3)    82 (21.5)
   Slowness of movements                                                                                            
    Experienced                                     50 (75.8)   90 (75.6)   157 (92.4)   227 (86.6)   207 (87.7)   317 (83.2)
    WO                                              27 (40.9)   42 (35.3)   122 (71.8)   153 (58.4)   149 (63.1)   195 (51.2)
   Reduced dexterity                                                                                                
    Experienced                                     36 (54.5)   85 (71.4)   143 (84.1)   219 (83.6)   179 (75.8)   317 (79.8)
    WO                                              18 (27.3)   37 (31.1)   101 (59.4)   145 (55.3)   119 (50.4)   182 (47.8)
   General stiffness                                                                                                
    Experienced                                     22 (33.3)   49 (41.2)   98 (57.6)    168 (64.1)   120 (50.8)   217 (57.0)
    WO                                              12 (18.2)   27 (22.7)   80 (47.1)    122 (46.6)   92 (39.0)    149 (39.1)
   Muscle cramps                                                                                                    
    Experienced                                     36 (54.5)   57 (47.9)   100 (58.8)   138 (52.7)   136 (57.6)   195 (51.2)
    WO                                              11 (16.7)   11 (9.2)    37 (21.8)    48 (18.3)    48 (20.3)    59 (15.5)
   Difficulty getting out of chair                                                                                  
    Experienced                                     24 (36.4)   36 (30.2)   98 (57.6)    137 (52.3)   122 (51.7)   173 (45.4)
    WO                                              6 (9.1)     11 (9.2)    62 (36.5)    79 (30.1)    68 (28.8)    90 (23.6)
   Anxiety                                                                                                          
    Experienced                                     42 (63.6)   49 (41.2)   112 (65.9)   123 (46.9)   154 (65.3)   172 (45.1)
    WO                                              10 (15.1)   13 (10.9)   46 (27.1)    45 (17.2)    56 (23.7)    58 (15.2)
   Sweating                                                                                                         
    Experienced                                     16 (24.2)   30 (25.2)   85 (50.0)    102 (38.9)   101 (42.8)   132 (34.6)
    WO                                              3 (4.5)     4 (3.4)     19 (11.2)    28 (10.7)    22 (9.3)     32 (8.4)
   Mood changes                                                                                                     
    Experienced                                     28 (42.4)   47 (39.5)   94 (55.3)    112 (42.7)   122 (51.7)   159 (41.7)
    WO                                              8 (12.1)    12 (10.1)   44 (25.9)    47 (17.9)    52 (22.0)    59 (15.5)
   Numbness                                                                                                         
    Experienced                                     11 (16.7)   19 (16.0)   53 (31.2)    52 (19.8)    64 (27.1)    71 (18.6)
    WO                                              2 (3.0)     2 (1.7)     16 (9.4)     17 (6.5)     18 (7.6)     19 (5.0)
   Panic attacks                                                                                                    
    Experienced                                     5 (7.6)     7 (5.9)     29 (17.1)    32 (12.2)    34 (14.4)    39 (10.2)
    WO                                              1 (1.5)     1 (0.8)     11 (6.5)     9 (3.4)      12 (5.1)     10 (2.6)
   Cloudy mind                                                                                                      
    Experienced                                     17 (25.7)   22 (18.5)   59 (34.7)    96 (36.6)    76 (32.2)    118 (31.0)
    WO                                              4 (6.1)     3 (2.5)     21 (12.3)    41 (15.6)    25 (10.6)    44 (11.5)
   Abdominal discomfort                                                                                             
    Experienced                                     19 (28.8)   30 (25.2)   53 (31.2)    48 (18.3)    72 (30.5)    78 (20.5)
    WO                                              1 (1.5)     2 (1.7)     11 (6.5)     13 (5.0)     12 (5.1)     15 (3.9)
   Feelings of hot/cold                                                                                             
    Experienced                                     11 (16.7)   16 (13.4)   51 (30.0)    53 (20.2)    62 (26.3)    69 (18.1)
    WO                                              2 (3.0)     2 (1.7)     14 (8.2)     12 (4.6)     16 (6.8)     14 (3.7)
   Pain                                                                                                             
    Experienced                                     29 (43.9)   26 (21.8)   73 (42.9)    75 (28.6)    102 (43.2)   101 (26.5)
    WO                                              8 (12.1)    5 (4.2)     29 (17.1)    23 (8.8)     37 (15.7)    28 (7.3)
   Aching                                                                                                           
    Experienced                                     14 (21.2)   31 (26.1)   67 (39.4)    88 (33.6)    81 (34.3)    119 (31.2)
    WO                                              5 (7.6)     11 (9.2)    33 (19.4)    41 (15.6)    38 (16.1)    52 (13.6)
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